



REVIEW ARTICLE / ПРЕГЛЕДНИ РАД

Application of fiberoptic bronchoscopy in the diagnosis and treatment of pneumonia in children

He Zhang^{1,2,3}, De-Xing Wang^{1,2}, Hai-Ming Yu^{1,2}

¹Baoding Hospital of Beijing Children's Hospital, Department of Respiratory Diseases, Baoding, Hebei, China;

²Baoding Key Laboratory of Clinical Research on Respiratory and Digestive Diseases in Children, Baoding, Hebei, China;

³Key Laboratory of the Pathogenesis and Precise Diagnosis and Treatment of Infectious Diseases in Children in Hebei Province, Hebei, China

SUMMARY

Pneumonia is a leading cause of morbidity and mortality in children, caused by various pathogens such as bacteria, viruses, mycoplasma, and fungi, each with distinct clinical manifestations. Fiberoptic bronchoscopy (FOB) is an invaluable tool for visualizing the airway, collecting lower respiratory tract specimens, and diagnosing and treating pediatric pneumonia. This review explores the role of FOB in managing pneumonia caused by different etiologies, including mycoplasma, adenovirus, and aspiration pneumonia. It also addresses the complications and precautions associated with FOB, emphasizing the importance of careful patient selection and the need for timely referrals to specialized centers, particularly in primary healthcare settings where access to FOB may be limited. The paper concludes with a discussion on the future development of FOB, focusing on advancements in technology, such as improved imaging, multi-modal functions, and artificial intelligence integration, which will enhance diagnostic accuracy and treatment efficacy for pneumonia.

Keywords: fiberoptic bronchoscopy; pneumonia; diagnosis; treatment; children

INTRODUCTION

Pneumonia is an inflammation of the pulmonary alveoli and interstitium, commonly seen in pediatric population – defined as individuals from birth to 18 years of age – and a leading cause of childhood mortality. The World Health Organization estimates that nearly two million children under the age of five die from pneumonia annually [1]. The disease is caused by various pathogens, including bacteria, viruses, mycoplasma, and fungi, with symptoms such as fever, cough, dyspnea, and chest pain [2, 3]. Epidemiological studies indicate that viruses are the most common cause of pediatric pneumonia, accounting for approximately 60–70% of cases in young children, with respiratory syncytial virus and influenza viruses being predominant [4]. Bacterial pathogens, particularly *Streptococcus pneumoniae*, are responsible for about 20–30% of cases, often in conjunction with or secondary to viral infections [5]. *Mycoplasma pneumoniae* (MPP) is increasingly recognized as a significant pathogen in school-aged children, contributing to 10–40% of community-acquired pneumonia cases in this age group [5]. Diagnosing and treating pneumonia requires a comprehensive approach, including medical history, clinical signs, laboratory tests, and imaging. However, diagnosis can be challenging, and treatment failures are frequent, particularly in primary

healthcare settings, where limited resources hinder early detection and effective management [6–9].

Fiberoptic bronchoscopy (FOB) is a crucial tool for visualizing the airway and collecting specimens from the lower respiratory tract, playing a vital role in diagnosing and treating pediatric respiratory diseases [10, 11]. Developed by a Japanese thoracic surgeon Shigeto Ikeda, FOB has become a cornerstone of modern pulmonary medicine [12]. In pediatric care, FOB is primarily used for airway inspection, removal of secretions or foreign bodies, sample collection, and placement of devices or drugs [13]. In primary healthcare settings, particularly in community hospitals with limited access to FOB, clinicians must understand its indications and recognize when referral to specialized centers is necessary. Timely referral can significantly improve the diagnosis and management of conditions like pneumonia. While several reviews have addressed bronchoscopy in pediatric respiratory diseases, this review is distinct in its focused evaluation of FOB's role across a broad pediatric age range, its emphasis on specific pneumonia etiologies such as mycoplasma, adenovirus, and aspiration, and its integration of recent technological advancements – including improved imaging, multi-modal functions, and AI-driven diagnostics – offering updated insights for both clinical practice and future research. This review

Received • Примљено:

April 24, 2025

Revised • Ревизија:

September 4, 2025

Accepted • Прихваћено:

September 5, 2025

Online first: September 29, 2025

Correspondence to:

De-Xing WANG
Baoding Hospital of Beijing
Children's Hospital
Department of Respiratory
No. 3399 Hengxiang North Street
Lianchi District
Baoding
Hebei
China
dexingw1984@163.com

highlights the importance of FOB in pediatric care and emphasizes its value in primary care settings. Understanding when to refer patients for FOB is essential for clinicians to improve the care of pediatric respiratory patients.

DIAGNOSTIC VALUE OF FOB IN PEDIATRIC PNEUMONIA

FOB allows direct observation of airway structure, identifying abnormalities such as stenosis, inflammation, and tumors. It also facilitates lower respiratory tract sample collection through bronchial irrigation, bronchoalveolar lavage (BAL), and biopsy. These samples support microbiological testing for bacteria, viruses, mycoplasma, fungi, and tuberculosis, enhancing diagnostic accuracy for pediatric pneumonia. In primary care, FOB is often used for repeated or unresolved pneumonia, unclear etiology, and suspected foreign body aspiration, prompting referrals for specialized care.

Evaluation of inflammatory response and immune status of the lungs

FOB, through BAL fluid (BALF), is essential for evaluating the inflammatory response and immune status of the lungs. Indicators such as cellular components, cytokines, and immunoglobulins in BALF reflect the degree of inflammation and immune responses. For example, an increased proportion of neutrophils suggests bacterial pneumonia, while lymphocyte dominance points to viral or tuberculous pneumonia. Elevated eosinophil counts indicate allergic or fungal pneumonia, and reduced pulmonary surfactant proteins are associated with alveolar surfactant deficiency, contributing to atelectasis and respiratory failure [14, 15, 16].

Assessment of lung structure and function

FOB also provides a detailed assessment of lung structure and function through bronchoscopic imaging. Key parameters, such as airway diameter, length, branching, angle, and wall thickness, are used to evaluate airway integrity and detect abnormalities like stenosis, deformity, inflammation, bleeding, or tumors. These findings are crucial for determining the location, extent, and severity of pneumonia, as well as airway damage. For instance, a reduction in airway diameter and length may suggest stenosis or collapse, while changes in branching or angle could indicate deformities. An increase in wall thickness may point to inflammation or tumors, and the presence of secretions or foreign bodies suggests obstruction or infection [17, 18, 19].

IDENTIFYING DIFFERENT TYPES OF PNEUMONIA

Unresolved or recurrent pneumonia

In pediatric pneumonia, cases that do not improve with antibiotics or where the etiology remains unclear, FOB is essential for identifying rare causes, such as atypical pathogens or complications like pleural effusion or lung abscesses. Early referral to a bronchoscopy-equipped facility ensures timely diagnosis and better outcomes.

Mycoplasma pneumonia, caused by MPP, accounts for 10–40% of pediatric pneumonia cases [20]. It typically presents with low fever, cough, sore throat, and headache, with patchy infiltrates on chest X-rays. Extrapulmonary symptoms, including erythema multiforme and myocarditis, are common [21]. Diagnosis relies on serology and molecular tests, though serology may suffer from cross-reactivity and molecular tests may yield false results [22]. FOB with BALF improves specificity, avoiding contamination. Cytological and pathological analysis of BALF enhances detection, and bronchoscopic imaging can identify mucous emboli, characteristic of severe mycoplasma pneumonia [23, 24].

Adenovirus pneumonia, responsible for 10–20% of pediatric pneumonia, particularly in children under five, presents with high fever, cough, dyspnea, and chest pain, with patchy infiltrates and pleural effusion on chest X-rays [25, 26]. Diagnosis depends on virological and molecular tests, but these can produce false results [27]. FOB enhances diagnostic accuracy by reducing upper respiratory contamination through BALF, enabling better immune response assessment. Bronchoscopic imaging can reveal airway abnormalities such as inflammation and necrosis [28, 29].

Aspiration pneumonia

Aspiration pneumonia, caused by inhaling gastric contents, vomit, or foreign bodies, is common in children with neurological impairments or swallowing difficulties, accounting for 5–15% of pediatric cases, particularly in newborns and infants [30]. It presents with wheezing, shortness of breath, and cyanosis, with chest X-rays showing patchy infiltrates and pleural effusion [31]. Diagnosis typically involves medical history, clinical signs, chest X-rays, and bronchoscopy, although sample quality may affect accuracy [32]. FOB is essential for diagnosis and management, as BALF helps identify aspirated material, improving specificity. Cytological and pathological analyses of BALF assess inflammatory responses, and bronchoscopy can directly visualize aspirated substances, characteristic of aspiration pneumonia [27, 33].

Timing of FOB in pediatric pneumonia

The timing of FOB is crucial for maximizing diagnostic yield and therapeutic benefit in pediatric pneumonia. For MPP pneumonia, particularly severe or refractory cases, FOB is recommended within 7–10 days of symptom onset,

especially if there is no clinical improvement after 48–72 hours of appropriate antimicrobial therapy. Early bronchoscopy during this window allows for effective removal of mucus plugs and mucous casts, which are prone to form during the peak inflammatory phase, thereby preventing bronchiolar obstruction and atelectasis [23, 24]. In adenovirus pneumonia, which often progresses rapidly and may lead to airway necrosis and post-infectious bronchiolitis obliterans, FOB should be performed earlier – ideally within the first 5–7 days of hospitalization – if there is clinical deterioration, persistent hypoxia, or radiological progression despite supportive care. This enables timely pathogen confirmation via BALF and intervention to clear necrotic debris [28, 29]. For aspiration pneumonia, FOB is most beneficial when performed acutely, within 24–48 hours of the suspected aspiration event, to directly visualize and remove aspirated material, reduce bacterial load, and prevent secondary chemical pneumonitis or infection. In chronically aspirating children, such as those with neurodevelopmental disorders, semi-elective FOB may be scheduled to evaluate recurrent pulmonary infiltrates or persistent symptoms, even in the absence of an acute event [32, 33]. Overall, the decision to perform FOB should balance the urgency of intervention with procedural risks, and close monitoring during the initial phase of illness is essential to identify the optimal time window for intervention.

THERAPEUTIC VALUE OF FOB IN PEDIATRIC PNEUMONIA

The therapeutic application of FOB in pediatric pneumonia should be guided by the stage of disease progression. Interventions differ significantly between the acute and recovery phases, with distinct priorities in each.

Acute phase interventions (first 1–2 weeks of illness)

During the acute phase, the primary goals of FOB are to restore airway patency, manage life-threatening obstructions, and support gas exchange. This phase is characterized by intense inflammation, mucus hypersecretion, and potential airway plugging – particularly in severe mycoplasma, adenovirus, and aspiration pneumonias. FOB is indicated for the immediate removal of viscous secretions, mucus plugs, necrotic debris, or aspirated material via suction, irrigation, or forceps extraction [34, 35]. In children with respiratory distress, hypoxemia, or atelectasis unresponsive to conventional therapy, such interventions can rapidly improve ventilation and prevent progression to respiratory failure [36]. Additionally, in cases of bronchial obstruction due to inflammatory casts or foreign bodies, timely FOB-guided clearance is critical to prevent irreversible lung damage. Direct instillation of saline lavage or mucolytic agents during this phase may further aid in breaking down tenacious secretions [37].

Recovery phase interventions (beyond two weeks or in persistent / recurrent cases)

In the recovery phase, FOB shifts from emergency intervention to diagnostic and rehabilitative roles. Persistent radiological infiltrates, prolonged oxygen dependence, or failure to thrive may indicate unresolved atelectasis, bronchial stenosis, or evolving airway complications such as bronchiectasis or bronchiolitis obliterans – particularly following severe adenovirus or mycoplasma infections [28, 29]. FOB during this phase allows for reassessment of airway integrity, clearance of residual secretions, and targeted delivery of anti-inflammatory agents (e.g., corticosteroids) or antibiotics directly to affected segments, enhancing local efficacy while minimizing systemic exposure [36, 37]. Furthermore, FOB enables the placement of airway stents or balloon dilation in cases of acquired bronchial stenosis, thereby improving long-term pulmonary function and reducing the risk of recurrent infections [38, 39]. Serial BAL in the recovery phase may also be used to monitor inflammatory markers and microbiological clearance, guiding the duration of therapy.

COMPLICATIONS AND PRECAUTIONS OF FOB

Despite the advantages of FOB in the diagnosis and treatment of pneumonia in children, FOB is associated with risks and complications. FOB-related complications are described below.

Anesthesia and sedation-related complications

Anesthesia and sedation are required in FOB, which may lead to anesthesia and sedation-related complications such as respiratory depression, arrhythmia, hypotension, and allergic reactions [36]. In order to reduce the incidence of these complications, it is necessary to fully evaluate the patients before the procedure, select appropriate anesthesia and sedatives, monitor the vital signs of patients, and promptly find out and handle abnormal conditions [40].

Airway-related complications

FOB is operated through the airway and may lead to airway-related complications, such as laryngospasm, bronchospasm, airway bleeding, airway injury, and pneumothorax [36]. It is important to select an appropriate bronchoscope model, avoid excessive operation, control the pressure of the airway, keep the airway moist, and promptly find out and handle abnormal conditions to reduce the incidence of these complications [35].

Infection-related complications

The bronchoscope may contact with the secretions or tissues of the lower respiratory tract during the process of FOB, and may consequently cause infection-related

complications, such as the spread of bacteria, viruses, mycoplasmas, and fungi, leading to cross-infection and nosocomial infections [36]. In order to reduce the incidence of these complications, it is essential that aseptic operation is strictly followed, bronchoscope and necessary instruments are thoroughly cleaned and disinfected, children are pre-treated with appropriate antibiotics for preventive purposes, and abnormal conditions are detected and handled promptly [41].

CONSIDERATIONS FOR FOB IN PEDIATRIC PNEUMONIA

Several issues need to be noted when FOB is used in the diagnosis and treatment of pneumonia in children, as described below.

Indications and contraindications of FOB

It is essential to understand the indications and contraindications of FOB when diagnosing and treating pneumonia in children to minimize risks. Indications include pneumonia with unclear etiology or treatment failure; severe pneumonia with complications like respiratory failure, difficult weaning, or organ dysfunction; pneumonia with airway blockages due to secretions or foreign bodies; pneumonia with airway abnormalities such as stenosis, deformities, inflammation, bleeding, or tumors; and cases requiring drug instillation or device placement in the airway [42]. Contraindications include severe systemic conditions like shock, coma, and massive bleeding; cardiovascular diseases such as heart failure, arrhythmia, and pericardial tamponade; coagulation dysfunction like thrombocytopenia; severe airway or lung abnormalities, including laryngeal edema, tracheal or esophageal fistulas, pleural effusion, and pneumothorax; and serious anesthesia or sedation risks, such as allergies and drug interactions [43].

Referral recommendations for FOB in primary healthcare settings

Given the limited availability of FOB in primary healthcare facilities, clinicians must recognize when referral to a specialized center is necessary. Referral indications include the following [15, 20, 21, 44]: if a child's pneumonia does not improve despite appropriate antimicrobial therapy or if the etiology remains unclear, FOB should be considered to identify atypical pathogens, foreign body aspiration, or underlying airway abnormalities not detected by routine methods. For severe pneumonia requiring intensive care or mechanical ventilation, FOB allows for a comprehensive airway assessment and pathogen identification, facilitating targeted treatment and better management of complications such as pleural effusion or bronchial obstruction. In cases of suspected aspiration pneumonia, especially in children with neurological conditions or feeding difficulties, FOB helps identify and remove aspirated material,

improving outcomes and preventing further complications. Additionally, when structural airway abnormalities like stenosis or tumors are suspected, FOB provides direct visualization to evaluate the extent of these issues and guide appropriate treatment, including surgical interventions. Finally, for cases requiring therapeutic interventions such as secretion removal, lavage, or device insertion, FOB offers the advantage of simultaneously providing diagnostic and therapeutic procedures, thereby optimizing patient management and outcomes.

Selection of appropriate FOB model and operation mode

When FOB is used in the diagnosis and treatment of pneumonia in children, the selection of an appropriate model and operation mode is required. Appropriate diameter, length, and curvature of fiberoptic bronchoscope should be selected based on factors such as the age, body weight, airway size, and conditions of children to avoid airway injury and operation difficulties caused by the inappropriate size of the bronchoscope [45]. At the same time, appropriate operation modes, including spontaneous breathing, mechanical ventilation, and high-frequency oscillatory ventilation are selected according to the factors of the children, such as respiratory pattern, airway pressure, and oxygenation level to avoid the incidence of intraoperative complications such as dyspnea, hypoxemia and high airway pressure [46].

Age-specific considerations in FOB application

The application of FOB varies significantly across pediatric age groups due to differences in airway anatomy, size, and physiological resilience. Neonates and infants have smaller airway diameters, increased airway compliance, and higher risks of hypoxia, requiring ultra-thin bronchoscopes (2–2.8 mm in diameter) and meticulous sedation management [47]. In contrast, older children and adolescents can tolerate larger scopes (3–4 mm) and may undergo procedures under moderate sedation with spontaneous breathing. Premature infants and those with underlying lung disease (e.g., bronchopulmonary dysplasia) are at increased risk for complications such as bronchospasm and desaturation. Furthermore, the indications for FOB may differ by age: viral and aspiration pneumonias are more common in infants and toddlers, while MPP predominantly affects school-aged children and adolescents [47]. Therefore, age-stratified approaches to patient selection, procedural planning, and post-procedure monitoring are essential to optimize safety and efficacy.

Combination with other examination and treatment methods

The diagnostic and therapeutic efficacy of FOB is significantly enhanced when integrated into a multimodal clinical strategy. FOB should be used in conjunction with

advanced imaging modalities such as chest computed tomography and point-of-care ultrasound, which provide complementary structural and functional information about the extent of pulmonary consolidation, pleural involvement, and airway dynamics [48]. BALF obtained via FOB can be analyzed using rapid molecular techniques – including multiplex polymerase chain reaction and next-generation sequencing – to identify pathogens with high sensitivity and specificity, particularly in cases of culture-negative or atypical pneumonia [49]. Furthermore, BALF enables host immune response profiling (e.g., cytokine and cellular analysis), which, when combined with serum biomarkers such as procalcitonin and C-reactive protein, supports differentiation between bacterial, viral, and inflammatory etiologies. Physiological assessments, including pulmonary function tests (when feasible in older children) and pulse oximetry monitoring during and after the procedure, further refine clinical decision-making. This integrative approach – combining FOB with imaging, molecular diagnostics, and systemic biomarkers – facilitates precise etiological diagnosis, monitors treatment response, and personalizes management strategies in children with complex or refractory pneumonia [50].

FUTURE DEVELOPMENT OF FOB

Remarkable achievements have been made for FOB in the diagnosis and treatment of pneumonia in children. However, there are still limitations and deficiencies in this technique, and further development and improvement are needed. Future developments of FOB are proposed and described below.

Pediatric applicability of advanced imaging technologies

While optical coherence tomography (OCT), endoscopic ultrasound (EUS), fluorescent bronchoscopy (FBS), and magnetic resonance bronchoscopy (MRBS) offer enhanced airway and parenchymal visualization, their application in children remains limited and largely investigational. OCT, which provides high-resolution cross-sectional imaging of airway walls, has shown potential in assessing bronchial inflammation and remodeling in adult chronic lung diseases, but its use in pediatric pneumonia is constrained by the small diameter of pediatric airways and the lack of suitably miniaturized probes compatible with ultra-thin bronchoscopes (2–2.8 mm) used in infants and young children [51]. Similarly, EUS-guided bronchoscopy, valuable for evaluating peribronchial lymphadenopathy or parenchymal consolidation, is rarely performed in children due to the size of current echo-bronchoscopes and the complexity of the procedure, which often requires general anesthesia and advanced expertise not widely available in pediatric centers [52]. MRBS, though non-invasive and radiation-free, is currently theoretical and faces significant technical hurdles in real-time airway navigation. Future

development must prioritize the design of pediatric-specific probes, rigorous safety studies, and clinical trials in pediatric populations to determine the diagnostic and therapeutic value of these technologies in childhood pneumonia and other respiratory conditions.

Improving the performance and functions of FOB

The performance and functions of future FOB should be enhanced by increasing the adjustability of related parameters such as the diameter, length, and curvature of the bronchoscope for children of different ages, body weights, and airway sizes, improving the quality of airway observation and diagnosis via increasing the clarity, resolution, and color of the bronchoscope, and enhancing the efficiency of airway operation and treatment via increasing the operability, flexibility, and stability of FOB [53].

Adding functions and accessories to FOB

More functions, such as optical, acoustic, electronic, and magnetic functions, will be added to future FOB for multi-modality imaging and examination, including OCT, EUS, FBS, and MRBS, to improve the structural and functional evaluation of the airways [51]. Meanwhile, accessories for fiberoptic bronchoscopes, such as various pliers, brushes, wires, catheters, stents, and balloons, will be added for multiple airway operations and treatments, including airway dilation, resection, biopsy, perfusion, and placement, to improve airway patency and stability [54].

Combining FOB with artificial intelligence and robotics

Artificial intelligence and robotics will be combined with FOB in the future. For instance, artificial intelligence and machine learning are used to analyze and identify the image and data obtained by FOB to improve the accuracy and objectivity of airway diagnosis and evaluation, for example, the identification of airway stenosis, deformity, inflammation, bleeding, and tumors, and evaluation of airway parameters, including diameter, length, branch, angle, and wall thickness, which can predict the prognosis and therapeutic effect of airway diseases [55]. In addition, robotic technology is used to optimize and automate the operation and control of fiberoptic bronchoscopes to improve the efficiency and safety of airway operation and treatment, including the accurate positioning, navigation, tracking, operation, and feedback for the airways [56].

In summary, while FOB has proven valuable in diagnosing and managing pediatric pneumonia, its application in primary healthcare settings remains limited due to equipment and expertise constraints. Therefore, it is crucial for clinicians to recognize when referral to specialized centers is necessary. Key indications for referral include unresolved pneumonia despite appropriate treatment, suspected aspiration pneumonia, or when structural airway abnormalities are suspected. Timely referral enables accurate

diagnosis, identification of atypical pathogens, and better management of complications, ultimately improving patient outcomes. Further advancements in FOB technology and training are essential to enhance its accessibility and effectiveness in pediatric care.

Ethics: The authors declare that the article was written in accordance with ethical standards of the Serbian Archives of Medicine as well as ethical standards of medical facilities for each author involved.

Conflict of interest: None declared.

REFERENCES

- World Health Organization. Pneumonia [EB/OL]. [2023-04-06]. <https://www.who.int/news-room/fact-sheets/detail/pneumonia>.
- Zhang H, Wang D, Ji H, Zhang J, Song Y. Distribution and epidemiological characteristics of common viruses in children with acute respiratory infection. *International Journal of Virology*. 2023;30(3):239–43. [DOI: 10.3760/cma.j.issn.1673-4092.2023.03.013]
- Zhu B, He Z, Zhou D, He S. Prevalence of asthma in children aged 3–12 years in Hebei province and the frequency distribution characteristics of susceptibility gene polymorphism. *Practical Preventive Medicine*. 2023;31(04):475–8. [DOI: 10.3969/j.issn.1006-3110.2024.04.023]
- Tang Z, Fan H, Tian Y, Lv Q. Epidemiological characteristics of six common respiratory pathogen infections in children. *Microbiol Spectr*. 2025;13(7):e0007925. [DOI: 10.1128/spectrum.00079-25] [PMID: 40401960]
- Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for *Mycoplasma pneumoniae* pneumonia in children. *J Microbiol Immunol Infect*. 2021;54(4):557–65. [DOI: 10.1016/j.jmii.2020.10.002] [PMID: 33268306]
- Zhang H, Ji H, An H, Cui Q, Yang F. Therapeutic effect of Jinzhen Oral Liquid combined with minocycline in treating refractory *Mycoplasma pneumoniae* pneumonia in children and its impacts on serum IL-6 and TNF- α levels. *Drug Evaluation Research*. 2025;48(06):1606–12. [DOI: 10.7501/j.issn.1674-6376.2025.06.020]
- Zhang H, Liu X, Song Y, Yu H. Efficacy and safety of methylprednisolone in adjuvant treatment of lobar pneumonia caused by *Mycoplasma pneumoniae* in children. *Journal of New Medicine*. 2020;51(8):624–7. [DOI: 10.3969/j.issn.0253-9802.2020.08.011]
- Yu H, Wang D, Liu X, Zhang H, Song Y. Predictive value of combined determination of serum PTX3 and copeptin in prognosis of children with severe pneumonia. *Journal of Hebei Medical University*. 2023;44(3):300–4. [DOI: 10.3969/j.issn.1007-3205.2023.03.011]
- Liu X, Zhang Y, Yu H, Zhang H, Sun Y. Effect of Methylprednisolone Sodium Succinate in the treatment of children with severe mycoplasma pneumonia and its effect on inflammatory factors. *China Medical Herald*. 2021;18(29):98–101. [DOI: 10.20047/j.issn1673-7210.2021.29.023]
- Zhang H, Liu X, Song Y, Yu H, Ji C, Li H, et al. Curative effect of fiberoptic bronchoscopy lavage on lobar pneumonia in children with different disease course. *Journal of Clinical and Pathological Research*. 2020;40(7):1734–9. [DOI: 10.3978/j.issn.2095-6959.2020.07.017]
- Zhang H, Liu X, Cao M, Song Y, Yu H, Ji C. Clinical observation of fiberoptic bronchoscopy lavage in children with lobar pneumonia of different courses. *Diet Health*. 2020;7(26):37.
- Ahn JH. An update on the role of bronchoscopy in the diagnosis of pulmonary disease. *Yeungnam Univ J Med*. 2020;37(4):253–61. [DOI: 10.12701/yujm.2020.00584] [PMID: 32891075]
- Golan-Tripto I, Mezan DW, Tsaregorodtsev S, Stiler-Timor L, Dizitzer Y, Goldbart A, et al. From rigid to flexible bronchoscopy: a tertiary center experience in removal of inhaled foreign bodies in children. *Eur J Pediatr*. 2021;180(5):1443–50. [DOI: 10.1007/s00431-020-03914-y] Erratum: *Eur J Pediatr*. 2021;180(5):1451. [DOI: 10.1007/s00431-021-03960-0] [PMID: 33389071]
- Bouazid D, Hingrat QL, Salipante F, Ferré VM, Chevallier T, Tubiana S, et al. Agreement of respiratory viruses' detection between nasopharyngeal swab and bronchoalveolar lavage in adults admitted for pneumonia: a retrospective study. *Clin Microbiol Infect*. 2023;29(7):942.e1–942.e6. [DOI: 10.1016/j.cmi.2022.12.024] [PMID: 36708772]
- Riedler J, Grigg J, Robertson CF. Role of bronchoalveolar lavage in children with lung disease. *Eur Respir J*. 1995;8(10):1725–30. [DOI: 10.1183/09031936.95.08101725] [PMID: 8586129]
- Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. *Eur Respir J*. 1999;13(6):1455–76. [DOI: 10.1183/09031936.99.13614779] [PMID: 10445627]
- De Palma A, Brascia D, Fiorella A, Quercia R, Garofalo G, Genuardo M, et al. Endoscopic removal of tracheobronchial foreign bodies: results on a series of 51 pediatric patients. *Pediatr Surg Int*. 2020;36(8):941–51. [DOI: 10.1007/s00383-020-04685-1] [PMID: 32468145]
- Wang S, Jiang Z, Li L, Zhang J, Zhang C, Shao C. Ameliorative effects of eosinophil deficiency on immune response, endoplasmic reticulum stress, apoptosis, and autophagy in fungus-induced allergic lung inflammation. *Respir Res*. 2021;22(1):173. [DOI: 10.1186/s12931-021-01770-4] [PMID: 34098934]
- Nursoy MA, Kilinc AA, Abdillahi FK, Ustabas Kahraman F, Al Shadfan LM, Sumbul B, et al. Relationships Between Bronchoscopy, Microbiology, and Radiology in Noncystic Fibrosis Bronchiectasis. *Pediatr Allergy Immunol Pulmonol*. 2021;34(2):46–52. [DOI: 10.1089/ped.2020.1319] [PMID: 33989070]
- Ding G, Zhang X, Vinturache A, van Rossum AMC, Yin Y, Zhang Y. Challenges in the treatment of pediatric *Mycoplasma pneumoniae* pneumonia. *Eur J Pediatr*. 2024;183(7):3001–11. [DOI: 10.1007/s00431-024-05519-1] [PMID: 38634891]
- Xu M, Li Y, Shi Y, Liu H, Tong X, Ma L, et al. Molecular epidemiology of *Mycoplasma pneumoniae* pneumonia in children, Wuhan, 2020–2022. *BMC Microbiol*. 2024;24(1):23. [DOI: 10.1186/s12866-024-03180-0] [PMID: 38229068]
- Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global Trends in the Proportion of Macrolide-Resistant *Mycoplasma pneumoniae* Infections: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2022;5(7):e2220949. [DOI: 10.1001/jamanetworkopen.2022.20949] [PMID: 35816304]
- Liu YN, Zhang YF, Xu Q, Qiu Y, Lu QB, Wang T, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study. *Lancet Microbe*. 2023;4(5):e330–e339. [DOI: 10.1016/S2666-5247(23)00031-9] [PMID: 37001538]
- Wang C, Li L, Xiao G, Chen Y, Wang Y, Chen Z, et al. Characteristics and Outcomes of *Mycoplasma Pneumoniae* Pneumonia Associated with Pulmonary Embolism and Necrotizing Pneumonia in Children. *Infect Drug Resist*. 2024;17:1961–9. [DOI: 10.2147/IDR.S459626] [PMID: 38779350]
- Mao NY, Zhu Z, Zhang Y, Xu WB. Current status of human adenovirus infection in China. *World J Pediatr*. 2022;18(8):533–7. [DOI: 10.1007/s12519-022-00568-8] Erratum: *World J Pediatr*. 2022. [DOI: 10.1007/s12519-022-00587-5] [PMID: 35716276]

Author Contributions

Zhang H conception, analysis of the data, and writing of the manuscript;

Wang DX critical review of significant intellectual value, final revision of the manuscript being prepared for publication;

Yu HM obtaining of results or analysis and interpretation of results;

All authors have read and approved the manuscript.

26. Zhang XP, Yang MY, Zhou X, Cao JS, Cai ZL, Kang XY, et al. [Clinical features of severe type 7 adenovirus pneumonia: an analysis of 45 cases]. *Zhongguo Dang Dai Er Ke Za Zhi*. 2020;22(5):429–34. Chinese. [DOI: 10.7499/j.issn.1008-8830.1911174] [PMID: 32434636]
27. Shuryaeva AK, Malova TV, Tolokonceva AA, Karccka SA, Gordukova MA, Davydova EE, et al. Development and application of LAMP assays for the detection of enteric adenoviruses in feces. *Microbiol Spectr*. 2022;10(4):e0051622. [DOI: 10.1128/spectrum.00516-22] [PMID: 35862966]
28. Hoge SP, Tudorache E, Pescaru C, Marc M, Oancea C. Bronchoalveolar lavage: role in the evaluation of pulmonary interstitial disease. *Expert Rev Respir Med*. 2020;14(11):1117–30. [DOI: 10.1080/17476348.2020.1806063] [PMID: 32847429]
29. Xu XH, Fan HF, Shi TT, Yang DY, Huang L, Jiang WH, et al. Influence of the timing of bronchoscopic alveolar lavage on children with adenovirus pneumonia: a comparative study. *BMC Pulm Med*. 2021;21(1):363. [DOI: 10.1186/s12890-021-01708-y] [PMID: 34763680]
30. Mandell LA, Niederman MS. Aspiration Pneumonia. *N Engl J Med*. 2019;380(7):651–63. [DOI: 10.1056/NEJMra1714562] [PMID: 30763196]
31. Xiang C, Huang L, Xia L. Mobile chest X-ray manifestations of 54 deceased patients with coronavirus disease 2019: Retrospective study. *Medicine (Baltimore)*. 2020;99(46):e23167. [DOI: 10.1097/MD.00000000000023167] [PMID: 33181691]
32. Cellina M, Orsi M, Toluian T, Valenti Pittino C, Oliva G. False negative chest X-Rays in patients affected by COVID-19 pneumonia and corresponding chest CT findings. *Radiography (Lond)*. 2020;26(3):e189–e194. [DOI: 10.1016/j.radi.2020.04.017] [PMID: 32423842]
33. Wrotek A, Robakiewicz J, Pawlik K, Rudzinski P, Pilarska I, Jaroń A, et al. The Etiology of Community-Acquired Pneumonia Correlates with Serum Inflammatory Markers in Children. *J Clin Med*. 2022;11(19):5506. [DOI: 10.3390/jcm11195506] [PMID: 36233374]
34. Han LL, Meng C, Zhang ZX, Tang XD, Ma J, Li CX. Clinical analysis of bronchoscope diagnosis and treatment for airway foreign body removal in pediatric patients. *Ital J Pediatr*. 2022;48(1):159. [DOI: 10.1186/s13052-022-01347-x] [PMID: 36056440]
35. Hamouda S, Oueslati A, Belhadj I, Khalsi F, Tinsa F, Boussetta K. Flexible bronchoscopy contribution in the approach of diagnosis and treatment of children's respiratory diseases: the experience of a unique pediatric unit in Tunisia. *Afr Health Sci*. 2016;16(1):51–60. [DOI: 10.4314/ahs.v16i1.7] [PMID: 27358613]
36. Kumar Subramani P, P N R, Narayanasamy D. The Role of Pulmonary Drug Delivery in Modern Therapeutics: An Overview. *Cureus*. 2024;16(9):e68639. [DOI: 10.7759/cureus.68639] [PMID: 39371739]
37. Zgherea D, Pagala S, Mendiratta M, Marcus MG, Shelov SP, Kazachkov M. Bronchoscopic findings in children with chronic wet cough. *Pediatrics*. 2012;129(2):e364–9. [DOI: 10.1542/peds.2011-0805] [PMID: 22232311]
38. Volsko TA, Parker SW, Deakins K, Walsh BK, Fedor KL, Valika T, et al. AARC Clinical Practice Guideline: Management of Pediatric Patients With Tracheostomy in the Acute Care Setting. *Respir Care*. 2021;66(1):144–55. [DOI: 10.4187/respcare.08137] [PMID: 33380501]
39. Saito Y, Imamura H. Airway stenting. *Surg Today*. 2005;35(4):265–70. [DOI: 10.1007/s00595-004-2942-y] [PMID: 15815840]
40. Mondal P, Dalal P, Sathiyadevan N, Snyder DM, Hegde S. Flexible Bronchoscopy Under Bronchoscopist-Administered Moderate Sedation Versus General Anesthesia: A Comparative Study in Children. *Pediatr Allergy Immunol Pulmonol*. 2018;31(3):166–73. [DOI: 10.1089/ped.2018.0887] [PMID: 30279995]
41. Yanik F, Sagiroglu G, Karamustafaoglu YA. Sublingual vs. intranasal dexmedetomidine sedation for flexible fiberoptic bronchoscopy procedure: a retrospective comparative study. *Eur Rev Med Pharmacol Sci*. 2023;27(23):11351–60. [DOI: 10.26355/eurrev_202312_34574] [PMID: 38095384]
42. Pattishall EN, Noyes BE, Orenstein DM. Use of bronchoalveolar lavage in immunocompromised children with pneumonia. *Pediatr Pulmonol*. 1988;5(1):1–5. [DOI: 10.1002/ppul.1950050102] [PMID: 2845341]
43. Frankel LR, Smith DW, Lewiston NJ. Bronchoalveolar lavage for diagnosis of pneumonia in the immunocompromised child. *Pediatrics*. 1988;81(6):785–8. [PMID: 2835744]
44. Kudagammana ST, Premathilaka S, Vidanapathirana G, Kudagammana W. Childhood mortality due to pneumonia; evidence from a tertiary paediatric referral center in Sri Lanka. *BMC Public Health*. 2024;24(1):3351. [DOI: 10.1186/s12889-024-20883-1] [PMID: 39623419]
45. Poddar B. Expanding the Scope of Flexible Fiberoptic Bronchoscopy in the PICU. *Indian J Crit Care Med*. 2023;27(5):303–4. [DOI: 10.5005/jp-journals-10071-24461] [PMID: 37214119]
46. Sachdev A, Chhawchharia R. Flexible Fiberoptic Bronchoscopy in Pediatric Practice. *Indian Pediatr*. 2019;56(7):587–93. [PMID: 31333214]
47. Paquette M, Magyar M, Renaud C. *Mycoplasma pneumoniae*. *CMAJ*. 2024;196(32):E1120. [DOI: 10.1503/cmaj.240085] [PMID: 39353637]
48. Yuan Y, Zhu Y. The application of fiber bronchoscope in children with severe pneumonia: a review. *Chinese Pediatric Emergency Medicine*. 2015:418–22.
49. Cui S, Guo R, Chen C, Zhang Y, Meng J, Liu L, et al. Next-Generation Sequencing for Characterizing Respiratory Tract Virome and Improving Detection of Viral Pathogens in Children With Pneumonia. *Influenza Other Respir Viruses*. 2024;18(8):e13362. [DOI: 10.1111/irv.13362] [PMID: 39118486]
50. Field-Ridley A, Sethi V, Murthi S, Nandalike K, Li ST. Utility of flexible fiberoptic bronchoscopy for critically ill pediatric patients: A systematic review. *World J Crit Care Med*. 2015;4(1):77–88. [DOI: 10.5492/wjccm.v4.i1.77] [PMID: 25685726]
51. Lee P, Sachdeva A. Interventional pulmonology: reflection on the past, perfecting the present and innovating for the future. *Curr Opin Pulm Med*. 2024;30(1):1–2. [DOI: 10.1097/MCP.0000000000001037] [PMID: 38051174]
52. Miller RJ, Casal RF, Lazarus DR, Ost DE, Eapen GA. Flexible Bronchoscopy. *Clin Chest Med*. 2018;39(1):1–16. [DOI: 10.1016/j.ccm.2017.09.002] [PMID: 29433707]
53. Aravena C, Mehta AC, Almeida FA, Lamb C, Maldonado F, Gildea TR. Innovation in rigid bronchoscopy-past, present, and future. *J Thorac Dis*. 2023;15(5):2836–47. [DOI: 10.21037/jtd-22-779] [PMID: 37324083]
54. Marchant BE, Morris BN, Royster RL. The video double-lumen tube: does it have a future? *J Thorac Dis*. 2023;15(5):2385–8. [DOI: 10.21037/jtd-23-309] [PMID: 37324104]
55. Gruionu LG, Udriștoiu AL, Iacob AV, Constantinescu C, Stan R, Gruionu G. Feasibility of a lung airway navigation system using fiber-Bragg shape sensing and artificial intelligence for early diagnosis of lung cancer. *PLoS One*. 2022;17(12):e0277938. [DOI: 10.1371/journal.pone.0277938] [PMID: 36476838]
56. Duke JD, Reisenauer J. Robotic bronchoscopy: potential in diagnosing and treating lung cancer. *Expert Rev Respir Med*. 2023;17(3):213–21. [DOI: 10.1080/17476348.2023.2192929] [PMID: 36939545]

Примена фиброоптичке бронхоскопије у дијагностици и лечењу пнеумоније код деце

Хе Џанг^{1,2,3}, Де-Синг Ванг^{1,2}, Хај-Минг Ју^{1,2}

¹Болница Пекиншке дечје болнице у Баодингу, Одељење за респираторне болести, Баодинг, Хебеј, Кина;

²Кључна лабораторија у Баодингу за клиничка истраживања респираторних и дигестивних болести код деце, Баодинг, Хебеј, Кина;

³Кључна лабораторија за патогенезу и прецизну дијагностику и лечење инфективних болести код деце у провинцији Хебеј, Хебеј, Кина

САЖЕТАК

Пнеумонија је водећи узрок морбидитета и морталитета код деце, а изазивају је разни патогени, као што су бактерије, вируси, микоплазме и гљивице, од којих сваки има специфичне клиничке манифестације. Фиброоптичка бронхоскопија (ФОБ) представља непроцењив алат за визуализацију дисајних путева, прикупљање узорка из доњих дисајних путева и дијагностиковање и лечење педијатријске пнеумоније. Овај преглед истражује улогу ФОБ-а у управљању пнеумонијом узрокованом различитим етиологијама, укључујући микоплазму, аденовирус и аспирациону пнеумонију. Такође се бави компликацијама и мерама опреза повезаним

са применом ФОБ-а, наглашавајући значај пажљивог избора пацијената и потребу за правовременим упућивањем у специјализоване центре, посебно у примарној здравственој заштити, где приступ ФОБ-у може бити ограничен. Рад се завршава дискусијом о будућем развоју ФОБ-а, са фокусом на напретку у технологији, попут побољшаног сликања, мултимодалних функција и интеграције вештачке интелигенције, што ће побољшати дијагностичку тачност и ефикасност лечења пнеумоније.

Кључне речи: фиброоптичка бронхоскопија; пнеумонија; дијагностика; лечење; деца